Results 51 to 60 of about 7,633 (200)

Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome [PDF]

open access: yes, 2023
Background & Aims Some patients with irritable bowel syndrome (IBS) demonstrate low-grade inflammation in the intestine. Mesalamine, which has anti-inflammatory effects, may be an efficacious treatment for IBS, but studies are conflicting.
Goodoory, V.C.   +7 more
core   +1 more source

Advancing Biotherapeutic Treatment of Ulcerative Colitis Using Lipid Mesophases: Formulation Design and Preclinical Validation

open access: yesAdvanced Science, EarlyView.
Lipid mesophases provide a versatile platform for colon‐targeted delivery of biotherapeutics, protecting them from degradation while enhancing mucoadhesion and enabling localized, controlled release to the inflamed mucosa after oral or rectal administration. In a DSS‐induced colitis model, this strategy reduced disease activity, inflammatory biomarkers,
Rafaela Gazzi   +13 more
wiley   +1 more source

Proteomic profile of human colon organoids: effects of a multi-mineral intervention alone and in the presence of pro-inflammatory and anti-inflammatory treatments

open access: yesFrontiers in Gastroenterology
IntroductionAquamin, a multi-mineral product derived from fossilized red marine algae, has been shown to improve colon barrier structure and function.
Muhammad Nadeem Aslam   +5 more
doaj   +1 more source

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

open access: yesJPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan   +2 more
wiley   +1 more source

Formulation, Evaluation and Comparison of Mesalamine compression coated tablets by using Natural and Semi synthetic polymers [PDF]

open access: yes, 2022
The main objective of this research paper is to formulate, evaluate and compare compression-coated tablets of Mesalamine using natural and synthetic polymer.
Joshna, B, Sirisolla, Janaki Devi
core   +1 more source

Mesalamine induced hepatotoxicity. Is mesalamine safe?

open access: yesRevista Española de Enfermedades Digestivas
Mesalamine is a medication used widely in the treatment of patients with inflammatory bowel disease. Although mesalamine is considered safe, hepatotoxicity has been reported with an incidence of 0-4%. We present the clinical picture of a patient with hepatotoxicity due to mesalamine.
Javier, Pérez-Valenzuela   +3 more
openaire   +2 more sources

A Versatile Microfluidic Manufacturing Platform for Macroscale Multicore Hydrogel Capsules Toward Programmable Oral Delivery of Therapeutics

open access: yesSmall, EarlyView.
This study presents a microfluidic fabrication method for millimeter‐scale multicore hydrogel capsules containing multiple aqueous cores physically isolated by oil layers. These macrocapsules exhibit mechanical and chemical robustness effectively protecting cargos under simulated gastric conditions.
Hye‐Seon Jeong   +4 more
wiley   +1 more source

Efficacy and Tolerance of 5-Aminosalicylic Acid Suppositories in the Treatment of Ulcerative Proctitis: A Review of Two Double-Blind, Placebo Controlled Trials

open access: yesCanadian Journal of Gastroenterology, 1990
The efficacy and tolerance of 500 mg 5-aminosalicylic acid (mesalamine) suppositories in the treatment of ulcerative proctitis were assessed in two double-blind, placebo controlled studies of six weeks' duration, involving a total of 173 patients.
CN Williams
doaj   +1 more source

Meta‐Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Advanced IBD therapies appear safe and effective in PSC‐IBD. However remission and response rates appear numerically attenuated compared to IBD‐only populations. Created in BioRender (https://BioRender.com/h9bxgij). ABSTRACT Background Inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) is a distinct phenotype (PSC‐IBD)
Amera Elzubeir   +6 more
wiley   +1 more source

Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers

open access: yesClinical Pharmacology: Advances and Applications, 2019
Abhijeet Jakate,1 Brian McNamee,2 Donald Burkindine31Clinical Pharmacology, Allergan plc, Madison, NJ, USA; 2Clinical Pharmacology, Allergan Biologics Ltd, Liverpool, UK; 3QPS Bio-Kinetic, Springfield, MO, USAObjective: Delayed-release mesalamine 400 mg ...
Jakate A, McNamee B, Burkindine D
doaj  

Home - About - Disclaimer - Privacy